Vascular endothelial growth factors tyrosine kinase inhibitors (VEGF-TKIs) are used in cancer therapy and anti-VEGF treatment is extensively studied according to the topic of retinal vein occlusion, diabetic retinopathy (DR), macular degeneration, and neovascular glaucoma. This evidence concerns the gene VEGFA and neovascular glaucoma.